Viridian Therapeutics

Quarterly Financials

Values in thousands 2024-06-30 2024-03-31 2023-12-31 2023-09-30
Revenue
$72
$72
$72
$72
Gross Profit
-5,719
-273
-278
-263
EBITDA
-64,254
-55,897
-65,794
-51,224
EBIT
-64,396
-56,242
-66,144
-51,559
Net Income
-64,992
-48,542
-66,860
-47,660
Net Change In Cash
72
72
72
72
Free Cash Flow
-46,162
-45,223
-38,048
-39,387
Cash
107,667
91,641
102,827
111,597
Basic Shares
63,854
61,099
49,681
43,654

Annual Financials

Values in thousands 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Revenue
$314
$1,772
$2,963
$1,050
Gross Profit
-1,008
1,017
2,343
-27,254
EBITDA
-235,365
-129,388
-79,290
-40,346
EBIT
-236,687
-130,143
-79,910
-40,885
Net Income
-237,734
-125,444
-79,416
-110,984
Net Change In Cash
314
1,772
2,963
1,050
Cost of Revenue
113,280
-3,598
21,051
Free Cash Flow
-185,068
-94,635
-54,919
-29,821
Cash
102,827
155,579
42,299
45,897
Basic Shares
44,755
32,087
11,918
3,557

Earnings Calls

Quarter EPS
2024-06-30
-$1.02
2024-03-31
-$0.79
2023-12-31
-$1.35
2023-09-30
-$1.09